Company intelligence

TXG

10x Genomics, Inc. · NASDAQ · Healthcare

Price$64.65-0.11% · −$0.07

Market cap8.21BEquity value

P / E-109.6Trailing ratio

Volume1.91MLatest session

Market data

TXG price chart

TradingView

Related signals

1 min delayed

Browse public TXG signals with their source context and measured market impact. Open any signal for its permanent analysis page.

TXGMar 31, 2026+6.12% since signal

10x Genomics Shares Surge on Strong Market Sentiment and Product Innovations

10x Genomics is witnessing a surge in share prices driven by increased market interest and recent product innovations. The growing demand for genomic research tools is anticipated to enhance sales forecasts, positioning TXG favorably for future growth.

View signal analysis

TXGFeb 13, 2025+3.31% since signal

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties

TXG reported Q4 EPS loss of $(0.40), missing estimates. Sales decreased 10% year-over-year but beat expectations at $165.02 million. Gross margin rose to 67% due to favorable product mix changes. Guidance for FY 2025 sales is lower than consensus at $610-$630 million. Analysts hold mixed ratings, with two downgrades and one maintained Buy.

View signal analysis

TXGOct 30, 2024-3.52% since signal

These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results

TXG reported a Q3 loss of 30 cents per share, better than expected. Quarterly sales were $151.654 million, missing estimates of $158.632 million. TXG reduced FY24 revenue guidance to $595-$605 million, down from $640 million. Analysts adjusted price targets, with mixed sentiments on the stock's future. Despite challenges, CEO remains optimistic about future customer outreach and execution.

View signal analysis

Research